Lysergic acid diethylamide
- Generic Name
- Lysergic acid diethylamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25N3O
- CAS Number
- 50-37-3
- Unique Ingredient Identifier
- 8NA5SWF92O
- Background
Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.
- Associated Conditions
- -
- Associated Therapies
- -
'Tofu-Like' Psychedelic Gets FDA Nod - Mindstate's AI-Designed Therapy To Begin Human Trials
Mindstate Design Labs received FDA and EMA approval for human trials of MSD-001, described as 'psychedelic tofu' for its mild effects. The trials aim to validate the neurotech AI platform, Osmanthus, designed to create tailored altered states of consciousness. CEO Dillan DiNardo envisions using psychedelics as tools to understand and design specific mental states, potentially addressing conditions beyond traditional psychedelic uses.
Cannabis and Hallucinogen Use Among Adults Remained at Historic Highs in 2023
Cannabis and hallucinogen use among adults remained at historic highs in 2023, while cigarette use stayed low. Alcohol use declined among younger adults but increased among older ones. Vaping trends rose, especially among younger adults. Gender differences in cannabis use reversed in younger adults but persisted in older ones. The study highlights the need for research on cannabis and hallucinogens.
FDA rejects psychedelic MDMA as treatment for PTSD, calling for additional study
FDA declined approval for MDMA as PTSD therapy, citing insufficient data and safety concerns, despite advocacy from veterans and mental health groups. Lykos Therapeutics plans to request reconsideration. This decision impacts the broader push for psychedelic treatments, with ongoing research into substances like psilocybin for mental health conditions.
Can psychedelics treat depression? Maybe, and you might not even have to take a trip
Dextromethorphan, a common cough medicine ingredient known for causing hallucinations at high doses, is now being used as an antidepressant in Auvelity, a drug approved by the FDA in 2022. Unlike traditional psychedelics, Auvelity combines dextromethorphan with buproprion to prevent hallucinations, offering a safer, trip-free treatment for depression. This development challenges the notion that hallucinogenic experiences are necessary for therapeutic benefits, with ongoing research exploring trip-free treatments for mental health conditions.
Ryzumvi: Pioneering Advances in Countering Drug-Induced Mydriasis
Mydriasis, excessive pupil dilation, causes vision issues. Ryzumvi, FDA-approved in 2023, treats drug-induced mydriasis effectively, with clinical trials showing safety and efficacy, though it has limitations like contraindications for uveitis and contact lens use.
Single dose of LSD provides immediate, lasting anxiety relief, study says
Mind Medicine Inc. announced FDA breakthrough therapy status for an LSD formulation, MM120, to treat generalized anxiety disorder, showing 48% remission at 12 weeks. The phase 2b trial highlighted significant clinical improvements without psychotherapy, marking a pivotal step in psychedelic treatment research.
Informed Consent to Psychedelic-Assisted Psychotherapy
Psychedelic-assisted psychotherapy (PAP) uses substances like psilocybin, LSD, and MDMA with therapy for conditions like PTSD and depression. It involves preparatory, medication, and integration sessions. Challenges include managing difficult experiences and ensuring informed consent, especially regarding session termination and therapeutic touch. Strategies to strengthen consent include psychiatric advance directives and dynamic consent, emphasizing trust and ethical considerations in PAP.
How I cured my ARFID with psychedelics
After 27 years struggling with ARFID, a restrictive eating disorder, the author found relief through self-administered psilocybin therapy, enabling them to try and enjoy new foods, marking a significant breakthrough in their lifelong battle with the disorder.
The Psychedelic Renaissance Is Here
The psychedelic renaissance is gaining momentum across medicine, therapy, and culture, with substances like psilocybin and MDMA nearing FDA approval for therapeutic use. States like Oregon and Colorado have decriminalized plant-based psychedelics, reflecting a shift in societal and legal attitudes. The Psychedelic Science 2023 conference highlighted the medical benefits of psychedelics, aiming for mainstream acceptance. Despite controversies over commercialization and cultural appropriation, the movement seeks to balance scientific research with spiritual and therapeutic applications, signaling a transformative era for psychedelics.
What role can psychedelics play in mental health?
The Minnesota Department of Health initiated the Psychedelic Medicine Task Force to explore the role of hallucinogenic drugs like MDMA, magic mushrooms, and LSD in legal, medical, and policy contexts. Other states have established centers to study these drugs' effects on mental health and substance use disorders under controlled conditions. Experts and listeners shared insights and experiences on psychedelics' impact on mental health.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath